Overview

Pre-Transplant INCBB099280 for Hepatocellular Carcinoma (HCC)

Status:
WITHDRAWN
Trial end date:
2028-09-01
Target enrollment:
Participant gender:
Summary
This is a pilot safety study of the oral PD-L1 inhibitor INCB099280 in patients with HCC awaiting liver transplant.
Phase:
PHASE1
Details
Lead Sponsor:
Abramson Cancer Center at Penn Medicine
Collaborator:
Incyte Corporation